Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach
RHEUMATOLOGY, cilt.60, sa.8, ss.3799-3808, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 60 Sayı: 8
- Basım Tarihi: 2021
- Doi Numarası: 10.1093/rheumatology/keaa863
- Dergi Adı: RHEUMATOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
- Sayfa Sayıları: ss.3799-3808
- Anahtar Kelimeler: inflammation, autoinflammatory conditions, quality of life care, outcome measures, DMARD, CHILDREN, RECOMMENDATIONS, MANAGEMENT, FMF
- İstanbul Üniversitesi Adresli: Evet
Özet
Objectives. Colchicine is the main treatment for FMF. Although a number of individuals with FMF are intolerant/resistant to colchicine, there is no standard definition of colchicine resistance/intolerance. We developed a set of evidence-based core statements defining colchicine resistance/intolerance in patients with FMF that may serve as a guide for clinicians and health authorities.